Braxia Scientific Corp (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida.  KetaMD onboarded new patients and completed initial ketamine treatments. Eligible patients, as determined by one of KetaMD’s licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their home.

KetaMD, Inc. (“KetaMD”), a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD).

In multiple studies, ketamine has also been shown to have rapid and persistent benefits for acute care in suicidal patients who often suffer from mental health challenges.  As National Suicide Awareness month kicks off, KetaMD has ramped up operations and session availability to provide additional support to Florida residents in need of treatment.

“We are incredibly proud to have treated our first patients in the U.S. through our KetaMD platform. KetaMD solves considerable issues by increasing access to innovative ketamine treatments for patients suffering from mental health disorders who don’t live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19.”

Dr. Roger McIntyre

Warren Gumpel, CEO of KetaMD commented, “We started building the model for KetaMD more than five years ago with the goal of deploying the latest technology to improve people’s lives and to empower those living with depression and other mental health conditions to take steps necessary to seek and receive safe, high quality, affordable, reliable care. We are working on scaling KetaMD beyond Florida across the U.S. opening up the opportunity for people to receive care anytime, from the comfort of their own homes.”

About KetaMD

KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments. Prescribed by medical professionals and guided by registered nurses via our secure platform, KetaMD is a safe and effective alternative for the millions of adults that currently rely on conventional mental health treatments to relieve depression, anxiety, and related mental health challenges. Our mission is to make this treatment safely accessible to those who need it across the United States. Through KetaMD’s program, adults who receive a qualifying diagnosis from one of our licensed medical prescribers may participate in our fully virtual program.

About Braxia Scientific Corp

Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders. Braxia also launched its U.S. based end-to-end telemedicine platform KetaMD utilizing leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.